Acorda Therapeutics (ACOR) Announces Pricing of $300 Million Of 1.75% Convertible Senior Notes Due 2021
6/18/2014 7:02:54 AM
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced the pricing of a public offering of $300 million principal amount of convertible senior notes due 2021 (the "Notes"). The Notes will bear interest at an annual rate of 1.75% and will mature on June 15, 2021, unless earlier converted, purchased or redeemed. Acorda granted the underwriter an option to purchase up to an additional $45 million principal amount of Notes to cover over-allotments, if any.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by